Novo Undercuts Lilly's Obesity Drug Price, Now Cheaper Than Car Payment

Core Viewpoint - Novo Nordisk A/S is reducing prices for its obesity drugs Wegovy and Ozempic to regain market share against Eli Lilly's offerings, following a recent agreement with the Trump administration aimed at lowering drug costs for patients [1][5]. Pricing Strategy - Starting immediately, introductory doses of Wegovy and Ozempic will be priced at $199 per month for the first two months for cash-pay patients, increasing to $349 per month thereafter, making them approximately 30% cheaper than Eli Lilly's Zepbound [2][5]. - The previous cost of over $1,000 per month for these drugs is now significantly reduced, making the new price of $349 per month more appealing compared to average car payments [2][4]. Market Context - The price cut aligns with a broader initiative to expand access to medications for obesity and chronic conditions, with Novo Nordisk emphasizing that these changes are being implemented ahead of the 2026 commitment [5]. - The announcement has led to a decline in Novo's stock price, which fell about 2% following the news and is down approximately 51% for the year [6]. Industry Insights - Analysts from Goldman Sachs have identified upcoming catalysts in the obesity-drug market, indicating ongoing developments and potential shifts in the competitive landscape [7].